A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study in Order to Investigate Safety and Efficacy of CP- 690 550 in Subjects With Moderate to Severe Ulcerative Colitis.

Trial Profile

A Randomized, Placebo Controlled, Double Blind, Parallel Group Multi-Center Study in Order to Investigate Safety and Efficacy of CP- 690 550 in Subjects With Moderate to Severe Ulcerative Colitis.

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Tofacitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Sponsors Pfizer
  • Most Recent Events

    • 01 Nov 2017 Results of an integrated analysis assessing safety of Tofacitinib in NCT00787202, NCT01458574, NCT01458951, NCT01465763 and NCT01470612 (n=1240) presented at the 25th United European Gastroenterology Week
    • 10 Jun 2017 Biomarkers information updated
    • 21 May 2013 Results reporting secondary endpoint of clinical remission presented at the Digestive Disease Week 2013.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top